Aclaris Therapeutics (ACRS)
(Delayed Data from NSDQ)
$1.15 USD
-0.06 (-4.96%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.15 0.00 (0.00%) 6:50 PM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
Brokerage Reports
Aclaris Therapeutics, Inc. [ACRS]
Reports for Purchase
Showing records 21 - 31 ( 31 total )
Company: Aclaris Therapeutics, Inc.
Industry: Medical - Drugs
Pipeline Progress Acceleration; 1Q22 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: POLLARD N
Company: Aclaris Therapeutics, Inc.
Industry: Medical - Drugs
Clinical Programs Advancing Apace; 2021 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aclaris Therapeutics, Inc.
Industry: Medical - Drugs
Zunsemetinib Mid-Stage Trial Details; Portfolio Expansion; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aclaris Therapeutics, Inc.
Industry: Medical - Drugs
Broadened Pipeline Becomes Apparent; 3Q21 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aclaris Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aclaris Therapeutics, Inc.
Industry: Medical - Drugs
New Boxed Warnings for JAK Inhibitors May Benefit ATI-1777; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aclaris Therapeutics, Inc.
Industry: Medical - Drugs
Multiple Candidates Advancing; 2Q21 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aclaris Therapeutics, Inc.
Industry: Medical - Drugs
Positive ATI-1777 Top-Line Phase 2a Data; Cash Replenished; Raising PT to $50
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aclaris Therapeutics, Inc.
Industry: Medical - Drugs
ATI-450 Target Indications Broaden; 1Q21 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aclaris Therapeutics, Inc.
Industry: Medical - Drugs
Managing Autoimmunity by Nuanced Kinase Inhibition; Initiate at Buy and $40 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aclaris Therapeutics, Inc.
Industry: Medical - Drugs
Managing Autoimmunity by Nuanced Kinase Inhibition; Initiate at Buy and $40 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R